1. Home
  2. LUMN vs ABVX Comparison

LUMN vs ABVX Comparison

Compare LUMN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lumen Technologies Inc.

LUMN

Lumen Technologies Inc.

HOLD

Current Price

$7.75

Market Cap

8.0B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$133.80

Market Cap

9.0B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUMN
ABVX
Founded
1968
2013
Country
United States
France
Employees
N/A
N/A
Industry
Telecommunications Equipment
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
9.0B
IPO Year
1972
N/A

Fundamental Metrics

Financial Performance
Metric
LUMN
ABVX
Price
$7.75
$133.80
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$5.73
$115.83
AVG Volume (30 Days)
11.8M
1.9M
Earning Date
02-03-2026
08-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,690,000,000.00
$6,231,374.00
Revenue This Year
N/A
$6.80
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.01
$4.77
52 Week High
$11.95
$148.83

Technical Indicators

Market Signals
Indicator
LUMN
ABVX
Relative Strength Index (RSI) 44.18 57.38
Support Level $7.50 $139.42
Resistance Level $7.94 $147.00
Average True Range (ATR) 0.37 7.25
MACD -0.04 0.98
Stochastic Oscillator 15.81 63.38

Price Performance

Historical Comparison
LUMN
ABVX

About LUMN Lumen Technologies Inc.

Lumen Technologies is one of the largest telecommunications carriers serving global enterprises. The merger with Level 3 in 2017 and the 2022 divestiture of much of its local phone business in rural areas and small markets shifted the company's operations away from the legacy consumer business and toward enterprises services, which account for about 75% of revenue. Lumen offers businesses a full suite of communications services, providing colocation and data center services, data transportation, phone service, and internet access. Lumen has announced the sale of its remaining consumer fiber network to AT&T, which will further shift its focus to enterprise customers.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: